Activation of the WNT/β-catenin pathway may also cause resistance to anti-BRAF therapy, and the combination of a WNT inhibitor (WNT974) with encorafenib and cetuximab is under evaluation for the treatment of BRAFV600E-mutant CRC (NCT02278133). Here, BRAF is linked to colorectal carcinoma.